367 related articles for article (PubMed ID: 30024443)
1. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
2. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
6. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Trojano M; Vila C
Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
[TBL] [Abstract][Full Text] [Related]
7. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Patti F
Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
[TBL] [Abstract][Full Text] [Related]
8. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
Maniscalco GT; Aponte R; Bruzzese D; Guarcello G; Manzo V; Napolitano M; Moreggia O; Chiariello F; Florio C
Neurol Sci; 2018 Jan; 39(1):97-102. PubMed ID: 29052091
[TBL] [Abstract][Full Text] [Related]
9. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Celius EG; Vila C
Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
[TBL] [Abstract][Full Text] [Related]
10. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
Patti F
Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
12. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
Di Marzo V; Centonze D
CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
[TBL] [Abstract][Full Text] [Related]
13. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
[TBL] [Abstract][Full Text] [Related]
14. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
15. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Montero-Escribano P; Vila Silván C
Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
[No Abstract] [Full Text] [Related]
16. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Gras A; Broughton J
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
[TBL] [Abstract][Full Text] [Related]
18. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
19. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Trojano M
Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
[TBL] [Abstract][Full Text] [Related]
20. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
